FeesSafety
Pluang+

FDA grants Orphan Drug Designation to onvansertib for treating rare leukemia CMML

Market News
21 Oct 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
FDA grants Orphan Drug Designation to onvansertib for treating rare leukemia CMML

Cardiff Oncology announced that the FDA has granted Orphan Drug Designation to onvansertib for treating chronic myelomonocytic leukemia (CMML), a rare and aggressive blood cancer with limited treatment options. This designation supports the development of onvansertib, a PLK1 inhibitor showing promising early clinical results in CMML patients, including improved blood counts and disease stabilization. The status provides benefits like tax credits and market exclusivity, aiding further clinical trials. Cardiff continues to explore onvansertib in other cancers, aiming to address unmet medical needs.

Cardiff Oncology's FDA Orphan Drug Designation for onvansertib is the subject here. For readers following the health sector, of 150 priced US stocks tradable on Pluang, 73 rose and 75 fell today. Notable movers include LQDA at USD 38.98 with a 7.24% increase, DXCM at USD 79.99 down 6.71%, and TNGX at USD 26.93 up 6.67%. These figures are as of Oct 22, 2026 03:02 WIB.

More News

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
17 minutes ago
AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

AMD stock soars 140% in 2026, Nvidia lags but both poised for strong earnings growth by 2028.

In 2026, AMD's stock surged 140% due to strong growth in AI chips and server CPUs, with revenue and earnings expected to continue rising sharply through 2028. Nvidia, despite a 20% stock drop and leadership uncertainty, reported impressive revenue an...

Market News
Neutral
26 minutes ago
Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway valued at $700 per share, driven by cash, stocks, and growing businesses under CEO Greg Abel.

Berkshire Hathaway holds $352 billion in cash and Treasury bills and a $336 billion stock portfolio, covering over half its current share price. CEO Greg Abel's patient management and steady growth in operating businesses, including railroad and util...

Market News
Bullish
47 minutes ago
Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead raises dividend for 11th year, backed by strong cash flow and expanding drug portfolio.

Gilead Sciences increased its dividend by 3.8% for the 11th consecutive year, supported by strong free cash flow of $10.6 billion over nine months and a conservative payout ratio below 30%. The company maintains a dominant position in HIV therapies w...

Company Fundamentals
Bullish
1 hour ago
Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia stock plunges 23% amid CEO resignation and investigations, trading at a record low P/E of 8.

Nvidia experienced its worst week since 2008, dropping 23% following CEO Jensen Huang's resignation and multiple investigations into chip exports to China. Despite a strong earnings report showing 103% revenue growth and raised guidance, the stock tr...

Market News
Bearish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App